MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Potential BlockBuster Technology and/or Business Model
FDA _ Regenerative Medicine Advanced Therapy (RMAT)
ProKidney Corp (NASDAQ:PROK)
Organization & Developments: ProKidney Corp
Parents
ProKidney Corp (NASDAQ:PROK)
Children
*Early clinical data suggest REACT may stop the progression of CKD, and may promote meaningful improvement in kidney function
*ProKidney is a late clinical-stage biotech company focused on the development of a pioneering cell therapy candidate that aims to transform the treatment landscape for Chronic Kidney Disease, with the potential to preserve kidney function and change patients' lives.
*Renal Autologous Cell Therapy: REACT™
2024: ProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel’s Registrational Path to Potential Approval in the U.S.
2024: ProKidney halts one CKD cell therapy phase 3 trial considered surplus to FDA approval
2024: ProKidney: Major Catalyst Is Too Far Away_seekingalpha.com
2024: The Prognosis For ProKidney: Unclear_ seekingalpha
2025: 2025 Will Be A Major Year For ProKidney's Rilparencel In CKD Treatment_seekingalpha.com
2025: ProKidney spikes after mid-stage trial data for lead asset
Jumps
Finance & Acquisitions: ProKidney Corp
Key People: ProKidney Corp